IP Library Granted Patent US 8,273,365
Granted Patent B2
US 8,273,365 · App. 13/433,287 · Granted Sep 25, 2012

Two-piece, internal-channel osmotic delivery system flow modulator

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,273,365
App. No.
13/433,287
Granted
Sep 25, 2012
Kind
B2
Abstract

An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.

Claims (37)

1. An implantable delivery system for an active agent formulation, comprising:

a reservoir made of an impermeable, metallic material;

a partition within the reservoir, the partition defining within the reservoir a first chamber and a second chamber;

the first chamber in the reservoir containing an osmotic engine;

the second chamber in the reservoir containing the active agent formulation;

a semipermeable plug disposed at a first end of the reservoir adjacent the first chamber; and

a flow modulator comprising (i) two pieces, an outer shell and an inner core, and (ii) an internal fluid channel, the flow modulator disposed at a second end of the reservoir adjacent the second chamber, the flow modulator comprising

the outer shell positioned in an opening at the second end of the reservoir, the outer shell comprising an inner surface,

the inner core inserted in the outer shell, the inner core comprising an outer surface, and

the internal fluid channel having a spiral shape defined between the outer shell and the inner core, wherein the outer shell and the inner core are made of a non-metallic material.

2. The implantable delivery system of claim 1 , wherein the fluid channel is formed on the outer surface of the inner core which mates with the inner surface of the outer shell.

3. The implantable delivery system of claim 1 , wherein the fluid channel is formed on the inner surface of the outer shell which mates with the outer surface of the inner core.

4. The implantable delivery system of claim 1 , further comprising a flow insert disposed between the outer shell and the inner core, wherein the fluid channel is formed in the flow insert.

5. The implantable delivery system of claim 4 , wherein the flow insert is made of a non-metallic material.

6. The implantable delivery system of claim 1 , wherein the outer shell sealingly engages the inner core.

7. The implantable delivery system of claim 1 , wherein the inner core further comprises an outer shoulder and the outer shell further comprises an inner shoulder, wherein the outer shoulder and inner shoulder engage to prevent expulsion of the inner core from the outer shell.

8. The implantable delivery system of claim 1 , wherein a length of the fluid channel ranges from 10 to 50 mm.

9. The implantable delivery system of claim 1 , wherein an effective cross-sectional diameter of the fluid channel ranges from 0.1 to 0.5 mm.

10. The implantable delivery system of claim 1 , wherein the active agent formulation comprises interferon-omega.

11. The implantable delivery system of claim 1 , wherein the flow modulator is press-fitted into the opening at the second end of the reservoir.

12. The implantable delivery system of claim 1 , wherein the non-metallic material of the outer shell and inner core comprises a polyaryletherketone, an ultra-high molecular weight polyethylene, a fluorinated ethylene-propylene, a polymethylpentene, or a liquid crystal polymer.

13. The implantable delivery system of claim 12 , wherein the polyaryletherketone is polyetheretherketone or polyaryletheretherketone.

14. The implantable delivery system of claim 1 , wherein the metallic material of the reservoir comprises gold-plated ferrous alloys, platinum-plated ferrous alloys, cobalt-chromium alloys, or titanium nitride coated stainless steel.

15. The implantable delivery system of claim 1 , wherein the metallic material of the reservoir comprises stainless steel, titanium, platinum, tantalum, gold, or alloys thereof.

16. The implantable delivery system of claim 1 , wherein the metallic material of the reservoir comprises titanium or a titanium alloy.

17. The implantable delivery system claim 1 , wherein the partition comprises a slidable piston.

18. A method of making an implantable delivery system for an active agent formulation, comprising:

positioning a piston within a reservoir, the piston defining within the reservoir a first chamber and a second chamber, wherein the reservoir is made of an impermeable, metallic material;

positioning an osmotic engine within the first chamber;

positioning a semipermeable plug in a first opening at a first end of a reservoir, adjacent the osmotic engine;

filling the second chamber with the active agent formulation; and

positioning a flow modulator in a second opening at a second end of the reservoir adjacent the active agent formulation, the flow modulator comprising

an outer shell positioned in the opening at the second end of the reservoir, the outer shell comprising an inner surface,

an inner core inserted in the outer shell, the inner core comprising an outer surface, and

a fluid channel having a spiral shape defined between the outer shell and the inner core, wherein the outer shell and the inner core are made of a non-metallic material.

19. The method of claim 18 , wherein the metallic material of the reservoir comprises titanium or a titanium alloy.

20. The method of claim 18 , wherein the non-metallic material of the outer shell and inner core comprises a polyaryletherketone, an ultra-high molecular weight polyethylene, a fluorinated ethylene-propylene, a polymethylpentene, or a liquid crystal polymer.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
Reel/Frame 052433/0001 →
RELEASE OF SECURITY INTEREST Recorded Jan 29, 2020
From: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C. AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 051739/0453 →
SECURITY INTEREST Recorded Oct 23, 2019
From: INTARCIA THERAPEUTICS, INC.
To: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENT
Reel/Frame 050801/0267 →
SECURITY INTEREST Recorded Oct 9, 2019
From: INTARCIA THERAPEUTICS, INC.; INTARCIA IRELAND LIMITED
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050673/0020 →
RELEASE OF SECURITY INTEREST Recorded Oct 23, 2015
From: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: INTARCIA THERAPEUTICS, INC.
Reel/Frame 036942/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2015
From: LAUTENBACH, SCOTT D.; DE LA SERNA, PEDRO E.; ZAMORA, PAULINE C.; DESJARDIN, MICHAEL A.
To: INTARCIA THERAPEUTICS INC.
Reel/Frame 035255/0803 →
SECURITY AGREEMENT Recorded Nov 14, 2012
From: INTARCIA THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 029299/0678 →